https://www.selleckchem.com/
5±1.3 years, were included. Mepolizumab significantly reduced the blood eosinophil count, as well as significantly decreased clinically significant exacerbation, in both populations. The OCS dosage was significantly reduced in patients treated receiving maintenance OCS therapy. However, mepolizumab did not improve lung function in either population, and no significant difference was observed in treatment responses between patients with asthma alone and ACO. Mepolizumab may be effective in elderly patients with eosinophilic asthma and ACO. Mepolizumab may be
Like
Comment
Share
